Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

Abstract Measurable residual disease (MRD) is strongly associated with risk of relapse and long‐term survival outcomes in patients with acute myeloid leukemia (AML). Apart from its clear prognostic impact, MRD information is also increasingly used to guide therapeutic decision‐making, including selection of appropriate patients for stem cell transplant, use of post‐transplant maintenance, and candidacy for non‐transplant maintenance therapies or MRD‐directed clinical trials. While much progress has been made in accurately assessing MRD and understanding its clinical importance, many questions remain about how to optimize MRD testing and guide treatment decisions for individual patients. In this review, we discuss the common methods to assess MRD in AML and the prognostic impact of MRD across common clinical scenarios. We also review emerging and investigational strategies to target MRD and discuss some of the important unanswered questions and challenges in the field.